RT Journal Article
T1 Risk of outcomes in a Spanish population with chronic kidney disease.
A1 Alcázar, Roberto
A1 Escobar, Carlos
A1 Palacios, Beatriz
A1 Aranda, Unai
A1 Varela, Luis
A1 Capel, Margarita
A1 Sicras, Antoni
A1 Sicras, Aram
A1 Hormigo, Antonio
A1 Manito, Nicolás
A1 Botana, Manuel
K1 SGLT2 inhibitors
K1 cardiovascular
K1 chronic kidney disease
K1 death
K1 renal
AB To assess mortality and cardiovascular and renal outcomes among patients with chronic kidney disease (CKD) (primary objective), with a particular focus on heart failure (HF) risk following diagnosis of CKD (secondary objective) in Spain. We conducted an observational study comprising cross-sectional and longitudinal retrospective analyses using secondary data from electronic health records. For the primary objective, adults with prevalent CKD [estimated glomerular filtration rate (eGFR)  In the prevalent population, 46 786 patients with CKD without HF [75.8 ± 14.4 years, eGFR 51.4 ± 10.1 mL/min/1.73 m2; 75.1% on renin-angiotensin system inhibitors (RASis)] and 8391 with CKD and HF (79.4 ± 10.9 years, eGFR 46.4 ± 9.8 mL/min/1.73 m2) were included. In the prevalent population, the risk of all-cause death {hazard ratio [HR] 1.107 [95% confidence interval (CI) 1.064-1.153]}, HF hospitalization [HR 1.439 (95% CI 1.387-1.493)] and UACR progression [HR 1.323 (95% CI 1.182-1.481)] was greater in those patients with CKD and HF versus CKD only. For the incident population, 1594 patients with CKD without HF and 727 with CKD and HF were included. Within 24 months from the CKD diagnosis (with/without HF at baseline), 6.5% of patients developed their first HF hospitalization. Although 60.7% were taking RASis, only 3.4% were at maximal doses and among diabetics, 1.3% were taking sodium-glucose cotransporter-2 inhibitors. The presence of HF among CKD patients markedly increases the risk of outcomes. CKD patients have a high risk of HF, which could be partially related to insufficient treatment.
SN 2048-8505
YR 2022
FD 2022-03-05
LK http://hdl.handle.net/10668/19745
UL http://hdl.handle.net/10668/19745
LA en
DS RISalud
RD Apr 8, 2025